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Background. Mexico and Central America are important travel destinations for North American and European
travelers. There is limited information on regional differences in travel related morbidity.
Methods. We describe the morbidity among 4779 ill travelers returned from Mexico and Central America who
were evaluated at GeoSentinel network clinics during December 1996 to February 2010.
Results. The most frequent presenting syndromes included acute and chronic diarrhea, dermatologic diseases,
febrile systemic illness, and respiratory disease. A higher proportion of ill travelers from the United States had acute
diarrhea, compared with their Canadian and European counterparts (odds ratio, 1.9; P , .0001). During the 2009
H1N1 influenza outbreak from March 2009 through February 2010, the proportionate morbidity (PM) associated
with respiratory illnesses in ill travelers increased among those returned from Mexico, compared with prior years
(196.0 cases per 1000 ill returned travelers vs 53.7 cases per 1000 ill returned travelers; P, .0001); the PM remained
constant in the rest of Central America (57.3 cases per 1000 ill returned travelers). We identified 50 travelers
returned fromMexico and Central America who developed influenza, including infection due to 2009 H1N1 strains
and influenza-like illness. The overall risk of malaria was low; only 4 cases of malaria were acquired in Mexico (PM,
2.2 cases per 1000 ill returned travelers) in 13 years, compared with 18 from Honduras (PM, 79.6 cases per 1000 ill
returned travelers) and 14 from Guatemala (PM, 34.4 cases per 1000 ill returned travelers) during the same period.
Plasmodium vivax malaria was the most frequent malaria diagnosis.
Conclusions. Travel medicine practitioners advising and treating travelers visiting these regions should dedicate
special attention to vaccine-preventable illnesses and should consider the uncommon occurrence of acute hepatitis
A, leptospirosis, neurocysticercosis, acute Chagas disease, onchocerciasis, mucocutaneous leishmaniasis, neuro-
cysticercosis, HIV, malaria, and brucellosis.
An estimated 13 million–20 million travelers visit
Mexico every year; .8 million arrive from the United
States, nearly 1 million from Canada, and approxi-
mately half a million from Europe [1]. More than
2.5 million US travelers visit Central America every
year [2]. Despite the large number of travelers to this
region and the availability of specific authoritative
pretravel preventive recommendations, such advice is
not frequently sought [3, 4].
We present data collected over 13 years from travelers
to Mexico and Central America who visited clinics
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affiliated with the worldwide GeoSentinel network. Our goal was
to provide evidence-based information on regional illness pat-
terns that could be used to update travel medicine recom-
mendations for future travelers to the region. In addition,
surveillance data collected during the 2009 H1N1 influenza
outbreak from these clinics provided an opportunity to study
the impact of the outbreak on travel-associated illness patterns
among visitors to Mexico and Central America.
METHODS
GeoSentinel sites are specialized travel or tropical medicine
clinics on 6 continents; providers from these clinics collect
sentinel surveillance data for all ill travelers who visit the clinic
during or after travel. These data include a broad sample of
travel destinations and of morbidity among persons who be-
come ill while traveling or when they return from travel.
Detailed methods for patient recruitment, inclusion criteria,
and limitations of the GeoSentinel database are described else-
where [5]. In brief, patients must have crossed an international
border within 10 years before the clinic visit and have sought
medical advice for a presumed travel-related illness. Anonymous
surveillance data (including travel history) that cannot be linked
to an individual patient are entered into a database at a central
data center. Final diagnoses are assigned codes by the treating
clinician from a standardized list of possible individual di-
agnoses that are also categorized under 21 broad syndromes. All
sites use the best available reference diagnostic test in their own
country. Patients can be assigned as many diagnosis codes as
needed. Because most infections are associated with fever, di-
agnoses predominantly localized to one organ system were in-
cluded in that organ-system syndrome category and were not
attributed to the broader category of systemic febrile disease.
The GeoSentinel data collection protocol underwent ethical
review and was classified as nonresearch public health surveil-
lance. As such, it was not subject to institutional review board
requirements.
Data entered into the GeoSentinel database from all sites from
11 December 1996 through 23 February 2010 were examined.
Data were extracted by identifying all travelers who were seen
after travel to Belize, Costa Rica, El Salvador, Guatemala,
Honduras, Mexico, Nicaragua, and Panama. These travelers
included tourists, students, business travelers, and persons vis-
iting friends or relatives.
Statistical Analysis
Proportionate morbidity (PM) was expressed as the number of
patients with a specific syndrome or diagnosis per 1000 ill
travelers returned from Mexico or Central America. Statistical
differences between groups were analyzed using the v2 test for
categorical variables and the Wilcoxon rank-sum test for
continuous variables. All diagnoses were examined and ranked
according to syndrome groups. The top 5 diagnoses in each of
the top 5 syndromic groups were queried from the database. A
subanalysis of the PM for the top 5 diagnoses compared age, sex,
pretravel advice, reason for travel, trip duration, and hospitali-
zation. The effect size of demographic and trip characteristics on
selected diagnoses was estimated using bivariate odds ratios
(ORs). A 2-sided P value# .05 was considered to be statistically
significant. SAS software, version 9.2 (SAS Institute) was used
for statistical calculations.
RESULTS
Demographic Characteristics of Travelers Returning From
Mexico and Central America
From December 1996 through February 2010, 4779 ill returned
travelers to Mexico and Central America were included. Females
represented 54% of the ill returned travelers. The mean age (6
standard deviation [SD]) was 35.9 6 14.7 years, with a median
trip duration of 17 days (interquartile range, 8–43 days). Most
were tourists (68%), followed by missionaries/aid workers/
volunteers (14%), business travelers (10%), travelers visiting
friends or relatives (5%), and students (3%). Two hundred
twenty-five ill returned travelers (5%) were hospitalized as
a result of a travel-related illness. Most (66%) of the travel
originated from the United States and Canada, 27% were from
Western Europe, and the remaining 12% traveled from the rest
of the world. Forty-eight percent of ill returned travelers had
sought pretravel advice from a health provider (Table 1). In-
dividuals traveling .7 days were more likely to have received
pretravel advice than were short-term travelers (50% vs. 29%;
OR, 2.4; 95% CI, 2.1–2.8; P , .0001).
Morbidity Patterns Among Travelers Returning From Mexico and
Central America
Overall, the most common syndrome groupings among ill
travelers returning from Mexico or Central America were acute
diarrhea, dermatologic, and systemic febrile illnesses, followed
by chronic diarrhea, other gastrointestinal, respiratory, non-
specific symptoms, and injuries and musculoskeletal illnesses
(Table 2). Dermatologic illness accounted for the highest PM
among ill returned travelers to Guatemala, Belize, Costa Rica,
and Panama (Table 3). Moreover, the PM for dermatologic
illness was nearly 2-fold higher than the PM for acute diarrheal
diseases among travelers to Costa Rica and Panama.
Ill returned travelers residing in the United States had sig-
nificantly higher PM for acute diarrhea after visits to Mexico
and Central America, compared with ill returned travelers
from Canada and Western Europe (P , .0001). Western
Europeans returning from Mexico and Central America had
a higher PM for chronic diarrhea, compared with their North
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American counterparts (P , .0001). Three hundred five
travelers with postinfectious irritable bowel syndrome (PI-
IBS), defined as diarrheal illness during travel, followed by
posttravel chronic abdominal pain (usually cramping and of
variable intensity) and altered bowel habits in the absence of
any organic cause of at least 12 weeks duration, and 24 ad-
ditional travelers with postinfectious lactose intolerance were
identified after they had returned home. The vast majority of
patients with PI-IBS were travelers from the United States and
Canada (90.3%), with the same proportion of men and
women affected (P5 .9). Ill returned travelers visiting friends
or relatives (P 5 .03) and students (P 5 .004) had the lowest
PM for PI-IBS, whereas missionaries (P , .0001) had the
highest PM, compared with tourists. Finally, older travelers
had less diarrhea, compared with their younger counterparts
(P 5 .0002). The PM for acute diarrheal illness was similar
among ill returning travelers who received pretravel advice,
compared with those who did not receive pretravel advice
from a travel medicine provider (P 5 .1).
Unspecified viral syndrome and dengue were the 2 most
common diagnoses among returned travelers with a systemic
febrile illness (Table 3). Fifty-seven cases of cutaneous myiasis
were diagnosed, most of them among travelers who had re-
turned from Belize (n 5 21; PM, 130.4 cases per 1000 patients)
and Costa Rica (n 5 22; PM, 35.4 cases per 1000 patients),
followed by Guatemala (n 5 6, PM, 15.2 cases per 1000 pa-
tients), El Salvador (n 5 1; PM, 10.1 cases per 1000 patients),
Nicaragua (n5 1; PM, 5.4 cases per 1000 patients), and Mexico
(n5 6; PM, 3.5 cases per 1000 patients). In addition, 61 cases of
cutaneous leishmaniasis were diagnosed: 41 from Costa Rica
(PM, 65.9 cases per 1000 patients), 7 from Belize (PM, 43.5 cases
per 1000 patients), 4 from Panama (PM, 29.2 cases per 1000
patients), 6 from Guatemala (PM, 15.2 cases per 1000 patients),
and 3 from Mexico (PM, 1.7 cases per 1000 patients).
Uncommon diagnoses seen among nonimmigrant travelers
included acute Chagas disease, fascioliasis, onchocerciasis,
neurocysticercosis, brucellosis, Bordetella pertussis infection,
leptospirosis, acute HIV infection, acute hepatitis A, and rubella
(Table 4).
Malaria Among Travelers Returning From Mexico and Central
America
Fifty-four cases of malaria among ill returned travelers who had
visited Mexico or Central America were identified over the past
10 years. Eighteen cases were identified in travelers returning
from Honduras, 14 from Guatemala, 4 from Costa Rica, 4 from
Mexico, 1 from Panama, and 1 from Belize. No cases were
identified among ill travelers returned from El Salvador or Ni-
caragua. Only 19 identified cases (36%) were in female in-
dividuals, and the mean age 6 SD was 36.7 6 12.3 years. Most
of the ill returned travelers with malaria were tourists (56.5%),
followed by missionaries (18.9%), travelers visiting friends and
relatives (11.3%), students (9.4%), and business travelers
(3.8%). Most of the identified malaria cases were due to P. vivax
(40), followed by Plasmodium falciparum [5], Plasmodium ovale
[2], and Plasmodium malariae [1]. Plasmodium species was not
determined for 6 cases. The highest PM for malaria among ill
returned travelers visiting the studied countries was in Hon-
duras (79.6 cases per 1000 patients), followed by Guatemala
(34.4 cases per 1000 patients), Panama (7.0 cases per 1000 pa-
tients), Costa Rica (6.1 cases per 1000 patients), Belize (5.8 cases
per 1000 patients), and Mexico (2.2 cases per 1000 patients).
Illness Patterns in Travelers Returning From Mexico and Central
America Before and After the H1N1 Influenza Pandemic
Some differences in characteristics of travelers to Mexico were
observed after the onset of the pandemic of 2009 H1N1 in-
fluenza. The proportion of ill returning leisure travelers from
Mexico remained constant after March 2009, when the H1N1
Table 1. Characteristics of Ill Travelers Returned From Mexico
and Central America Seen at a GeoSentinel Network Clinic From
11 December 1996 through 23 February 2010
All travelers (N 5 4779)Characteristic
Female 2543 (54)
Mean age (SD) 35.9 (14.7)
Trip duration (median days, IQR) 17 (8–43)
Sought pretravel advice 2094 (48)
Travel reason
Business 493 (10)
Tourism 3239 (68)
Student 139 (3)
Missionary 653 (14)
Visiting friends and relatives 231 (5)
Patient type
Outpatient 4428 (95)
Inpatient 225 (5)
Region of origina
North America 3149 (66)
Central America 31 (0.7)
South America 16 (0.3)
Caribbean 1 (0.02)
Western Europe 1285 (27)
Eastern Europe 1 (0.02)
Middle East 189 (4)
North East Asia 34 (0.7)
South Central Asia 1 (0.02)
South East Asia 4 (0.08)
Sub-Saharan Africa 4 (0.08)
Oceania 62 (1)
NOTE. Central American countries include Belize, Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua, and Panama. Data are number (%) of patients,
unless otherwise indicated. IQR, interquartile range; SD, standard deviation.
a Based on country of current residence.
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influenza outbreak was identified, but the proportion of those
who obtained pretravel health advice decreased (P, .0001). The
proportion of hospitalizations also increased among ill travelers
returning from Mexico after H1N1 influenza (P , .0001).
The pattern of respiratory illnesses diagnosed in ill travelers
returned fromMexico and Central America is shown in Figure 1.
The mean monthly PM for respiratory illnesses among ill re-
turned travelers visiting Mexico from December 1996 through
February 2009 increased 4 times during the period after the
influenza outbreak was identified in March 2009 (53.7 vs 196.0
cases per 1000 patients; P , .0001) but remained constant for
the rest of Central America.
Among ill returned travelers who had a respiratory presenting
symptom, unspecified upper respiratory tract infections remained
the most common diagnosis before (PM, 18.6 cases per 1000
patients) and after (PM, 59.8 cases per 1000 patients; P , .0001)
31 March 2009, when the H1N1 influenza outbreak was identi-
fied. From April 2009 through February 2010, the PM for in-
fluenza, influenza-like illness (P , .0001), and acute bronchitis
(P , .02) also increased. Fifty ill returned travelers who visited
Mexico and Central America developed influenza, including in-
fection due to H1N1 strains, and influenza-like illness.
DISCUSSION
Using a sample of 4779 ill returned travelers, we elucidated illness
patterns for Mexico and Central America that can direct pretravel
advice and diagnosis of illness in future travelers to the region.
Consistent with prior reports from this and other developing
regions, diarrhea is the most common reason for seeking post-
travel medical care [5]. As shown by Alon et al [6], we observed
that elderly ill returned travelers had a lower PM for diarrhea,
compared with younger travelers. This observed lower proportion
of diarrhea among older travelers could possibly be attributed to
increased dietary caution in this age group, the development of
immunity from earlier travel, or the possibility that the older
travelers have comparatively greater numbers of visits for other
health problems. As noted elsewhere [7], visiting a travel medicine
practitioner for medical advice before visiting Mexico and Central
America was not associated with a lower proportion of acute
diarrhea among the studied population, although this dataset
does not allow an assessment of the benefit of seeking advice. One
explanation is the possibility that travelers who seek pretravel
medical advice at a travel clinic tend to return to the same clinic
(ie, a GeoSentinel clinic) if they are sick, whereas those who did
not seek pretravel health advice tend to go elsewhere for posttravel
problems and are not captured in the GeoSentinel database.
Travelers who seek pretravel advice may also be more likely to
consult for posttravel symptoms, in general.
We observed a large difference in PI-IBS and chronic diarrhea
diagnoses between North Americans and Europeans; whereasTa
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Table 3. Proportionate Morbidity (PM) Per 1000 Ill Travelers Visiting a GeoSentinel Network Clinic After Travel
Mexico PM Guatemala and Belize PM Honduras, El Salvador, and Nicaragua PM Costa Rica and Panama PM
Respiratory Respiratory Respiratory Respiratory
Upper respiratory tract infection 24.1 Upper respiratory tract infection 12.4 Upper respiratory tract infection 15.8 Upper respiratory tract infection 17.9
Influenza-like illness 8.9 Acute bronchitis 4.1 Influenza-like illness 6.3 Acute bronchitis 8.4
Acute bronchitis 8.5 Mycobacterium TB, pulmonary 4.1 Acute bronchitis 4.7 Acute sinusitis 7.4
Pneumonia, bacterial 5.4 Influenza-like illness 2.7 Pneumonia, bacterial 3.2 Influenza-like illness 4.2
Acute sinusitis 4.5 Asthma 1.4 Acute sinusitis 3.2 Influenza A 2.1
Acute diarrhea Acute diarrhea Acute diarrhea Acute diarrhea
Acute unspecified diarrhea 89.0 Acute unspecified diarrhea 93.4 Acute unspecified diarrhea 91.5 Acute unspecified diarrhea 59.9
Acute bacterial diarrhea a 44.7 Giardia 26.1 Giardia 20.5 Acute bacterial diarrhea a 28.4
Giardia 26.4 Acute bacterial diarrhea a 23.4 Acute bacterial diarrhea a 18.9 Giardia 27.3
Gastroenteritis b 17.0 Ameba infections 9.6 Dientamebiasis (D. fragilis) 12.6 Campylobacter 12.6
Ameba infections 14.3 Dientamebiasis (D. fragilis) 8.2 Ameba infections 9.5 Gastroenteritis 11.6
Dermatologic Dermatologic Dermatologic Dermatologic
Cutaneous larva migrans 31.3 Insect bite 54.9 Insect bite 37.9 Insect bite 53.6
Insect bite 20.6 Myiasis 49.5 Cutaneous larva migrans 23.7 Cutaneous leishmaniasis 50.4
Unspecified rash 17.4 Unspecified rash 23.4 Unspecified rash 12.6 Unspecified rash 36.8
Photosensitivity rash 9.8 Cutaneous larva migrans 19.2 Fungal infection 11.0 Myiasis 23.1
Skin abscess 7.6 Cutaneous leishmaniasis 19.2 Rash, contact dermatitis 7.9 Insect bite, superinfected 17.9
Systemic illness Systemic illness Systemic illness Systemic illness
Unspecified viral syndrome 42.0 Unspecified viral syndrome 38.5 Unspecified viral syndrome 50.5 Unspecified viral syndrome 56.7
Dengue infection 13.0 Dengue infection 34.3 Dengue infection 36.3 Dengue infection 31.5
Febrile illness, unspecified ($3 weeks) 6.3 Malaria, P. vivax 15.1 Histoplasmosis 23.7 Febrile illness, unspecified (,3 weeks) 21.0
Epstein-Barr virus infection 5.8 Histoplasmosis 12.4 Malaria, P. vivax 20.5 Leptospira 9.5
Febrile illness, unspecified (,3 weeks) 5.8 Cellulitis 9.6 Febrile illness, unspecified (,3 weeks) 11.0 Cellulitis 4.2
Chronic diarrhea Chronic diarrhea Chronic diarrhea Chronic diarrhea
Post-infectious IBS 73.8 Post-infectious IBS 63.2 Post-infectious IBS 61.5 Unspecified chronic diarrhea 30.5
Unspecified chronic diarrhea 51.9 Unspecified chronic diarrhea 54.9 Unspecified chronic diarrhea 48.9 Post-infectious IBS 29.4
NOTE. Top 5 individual diagnoses among selected main syndrome groups for patients with disease acquisition in Mexico and Central America from 11 December 1996 through 23 February 2010. Based on exposure
country, if ascertainable as determined by clinician (N 5 4970, patients can have $1 diagnosis).
a Refers to acute diarrhea due to a bacterial pathogen other than Clostridium difficile, Campylobacter species, Vibrio cholerae, Salmonella species, and Shigella species, which each one have a distinct diagnostic code.
b Refers to individuals with predominant upper gastrointestinal disease with major component of nausea and vomiting with accompanying diarrhea.
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travelers from the United States and Canada had a higher PM for
PI-IBS, European travelers had a higher PM for chronic di-
arrhea. This finding may represent a difference in the definition
and use of these diagnoses among medical practitioners on the
different continents.
Dermatologic illnesses had an important impact on travelers,
especially those visiting Guatemala, Belize, Costa Rica, and
Panama. The increased PM for dermatologic illnesses might be
explained by a higher proportion of travelers visiting these areas
for eco-travel, spending time in the forest and/or jungle, and
sleeping in remote areas. Myiasis in Belize seems especially
common. Most of the cutaneous leishmaniasis cases were di-
agnosed in travelers who had visited Costa Rica and Belize.
Although cutaneous leishmaniasis is an endemic disease in
Central America, mucocutaneous [8] and visceral [9] leish-
maniasis are rarely identified. Mucocutaneous leishmaniasis was
confirmed in a 64-year-old German man who traveled to Costa
Rica during February 2004. Travelers to Central America should
be advised on measures to prevent insect bites and secondary
infections of these lesions and management of cuts and small
injuries that can predispose to cellulitis and prevention of der-
matophytes.
Vaccine-preventable illnesses were observed among ill re-
turned travelers from developed nations, where vaccines are
widely available. These cases included a 68-year-old American
man traveling to Guatemala during January 2007 and a 24-year-
old American woman traveling to Costa Rica during June 2009,
both of whom received a diagnosis of pertussis. Seven travelers
from the United States, Canada, and Israel who returned from
Mexico and Central America during January 2000–October
2007 received a diagnosis of acute hepatitis A infection; the
youngest was 7 years of age, and the oldest was 57 years of age. In
addition, a rubella case was identified in a 33-year-old female,
Brazilian US resident traveling to Costa Rica in 2008. As was
shown by Boggild et al [10], these findings highlight the im-
portance of using the pretravel consultation to catch-up on
routine vaccinations that may have been missed and those in-
dicated primarily for travel.
Table 4. Characteristics of Ill Travelers With Selected Infectious Diseases After Visiting Mexico and Central America, Seen After Travel
at a GeoSentinel Network Clinic From 11 December 1996 through 23 February 2010
Individual diagnosis Traveler origin Age Sex Traveler destination Date of travel Type of travel Pretravel advice
Acute chagas disease Canada 26 Female Mexico Jun 2008 Tourist UNK
Fascioliasis Germany 58 Female Mexico Jun 2000 Tourist Yes
Onchocerciasis United States 31 Male Guatemala May 2005 Business UNK
Mucocutaneous
leishmaniasis
Germany 64 Male Costa Rica Feb 2004 Tourist Yes
Neurocysticercosis United States 20 Male Guatemala Jul 2002 Missionary No
Neurocysticercosis United States 23 Female Guatemala Oct 2002 Missionary Yes
Acute brucellosis United States 33 Female Mexico Aug 2003 Visiting Friends
and Relatives
No
Chronic brucellosis United States 24 Female Honduras Feb 2008 Tourist Yes
Pertussis United States 68 Male Guatemala Jan 2007 Tourist Yes
Pertussis United States 24 Female Costa Rica Jun 2009 Tourist No
Leptospirosis Canada 37 Female Costa Rica Apr 2000 Tourist No
Leptospirosis United States 55 Male Panama Feb 2005 Tourist No
Leptospirosis United States 30 Male Panama Nov 2007 Tourist No
Leptospirosis France 48 Female Costa Rica Jul 2008 Business UNK
Leptospirosis United States 24 Female Costa Rica Dec 2008 Tourist No
Leptospirosis United States 33 Male Costa Rica Oct 2009 Tourist No
Acute HIV Canada 30 Male Mexico Nov 2002 Missionary UNK
Acute HIV Switzerland 43 Male Central America Aug 2005 Tourist UNK
Acute hepatitis A Israel 24 Male Nicaragua Jan 2000 Tourist No
Acute hepatitis A Canada 28 Female Central America May 2000 Tourist No
Acute hepatitis A USA 55 UNK Mexico Mar 2005 Tourist No
Acute hepatitis A USA 49 Female Mexico Aug 2005 Tourist No
Acute hepatitis A Canada 57 Male Mexico Apr 2007 Tourist UNK
Acute hepatitis A Canada 56 Female Mexico Apr 2007 Tourist UNK
Acute hepatitis A USA 7 Female Mexico Oct 2007 Visiting friends
and relatives
UNK
Rubella Brazil 33 Female Costa Rica Mar 2008 Visiting friends
and relatives
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A statistically significant decrease in the number of imported
malaria cases from Latin America in the United States was noted
during 2007–2008 [11]. Although our study was not designed to
provide an assessment of current malaria risk and prophylactic
effectiveness among travelers, the PM for malaria in Honduras
(79.6 cases per 1000 persons) and Guatemala (34.4 cases per
1000 persons) was found to be significantly higher than in the
other studied countries. Most of the identified malaria cases in
the GeoSentinel database were caused by P. vivax rather than
P. falciparum, and some cases might represent previously ac-
quired relapsing disease [12]. We identified 4 malaria cases in
Mexico, including 2 in US leisure travelers who visited Tulum
(located in the state of Quintana Roo, bordering Guatemala)
during January 2007 and were hospitalized after their return.
The other 2 malaria cases, presumably acquired in Mexico, were
in adult Canadians traveling during 2000; however, complete
travel information and exposure details were not available.
Malaria transmission in Mexico continues to decrease, and
chemoprophylaxis against malaria is not routinely indicated for
travelers visitingMexico except some rarely visited regions, most
notably, in Chiapas and Oaxaca. For Central America, detailed
recommendations can be found on the Centers for Disease
Control and Prevention Travelers’ Health Web site (www.cdc.
gov/travel). In general, only travelers to Costa Rica, Panama west
of the canal, or El Salvador will require chemoprophylaxis.
Beginning in April 2009, the GeoSentinel Surveillance Net-
work recorded an increased PM associated with all respiratory
illnesses. During the 2009 H1N1 influenza outbreak, an in-
creased awareness of the potential health risks of traveling to
Mexico among returning travelers may have also led to the in-
creased numbers of patients visiting travel medicine clinics for
2009 H1N1 influenza screening. Some differences among trav-
elers to Mexico were observed after the onset of the 2009 H1N1
influenza pandemic. The proportion of ill leisure travelers re-
turning from Mexico remained constant after March 2009,
when the H1N1 influenza outbreak was identified. Because the
proportion of travelers who obtained pretravel health advice
decreased, we hypothesize either that those who consulted
health care practitioners before travel were advised not to travel
to this area or that most of the leisure travelers visiting Mexico
during the H1N1 influenza outbreak chose not to visit a travel
medicine clinic. The increase in hospitalizations may have been
a result of travelers being more likely to consult for respiratory
symptoms, because of the general concern about H1N1 in-
fluenza at the time.
This descriptive analysis from the GeoSentinel database has
several limitations. First, the database represents ill travelers
seeking medical care at GeoSentinel sites; thus, the data do not
represent a comprehensive epidemiologic analysis of all trav-
elers. Second, because no information related to healthy trav-
elers was recorded and no denominator was available, we could
not estimate rates or risk of travel-related illness. Third, because
most GeoSentinel sites are travel or tropical medicine clinics
located in Europe and North America, diseases with short in-
cubation periods and/or self-limited symptoms that might
manifest during travel may be underrepresented in the database.
Fourth, GeoSentinel clinics tend to be referral clinics. As such,
diseases with more severe, persistent, or complex and/or unusual
Figure 1. Monthly proportionate morbidity per 1000 ill travelers returned from Mexico and Central America who received diagnoses of respiratory
illnesses, seen at a GeoSentinel Network clinic, from 11 December 1996 through 23 February 2010.
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clinical signs or symptoms might be overrepresented. Fifth,
some GeoSentinel clinics might have different proportions of
certain types of travelers; for example, American clinics are more
likely to see more travelers visiting friends or relatives in Latin
America, because of the higher proportion of Hispanic residents
in the United States. Sixth, the GeoSentinel database is designed
to collect epidemiologic information based on the diagnosis
made by the practitioner seeing the ill traveler and depends on
the best knowledge and resources available locally. Seventh, the
GeoSentinel database collects predefined epidemiologic in-
formation and not additional detailed clinical information, such
as the administration of prophylaxis, vaccines, or medication
used by the traveler while in the destination country. Last,
a proportion of exposure countries were missing or un-
ascertainable as determined by the clinician; analysis based on
exposure country may not be representative of travelers exposed
in Mexico or Central America.
The information presented here provides a profile for
practitioners seeing travelers returned from Mexico and
Central America. The differences in proportionate morbid-
ities seen in different regions of Central America can help
guide pretravel interventions. In addition, this study describes
the impact of the H1N1 influenza epidemic in Mexico and
Central America on respiratory illness in returning travelers
and illustrates how the GeoSentinel network can reflect such
an outbreak.
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